John Fowler, cofounder and CEO of Kezar Life Sciences, shares “A Letter to Kezar Employees,” a best practice example of a leader communicating authentically and transparently during times of crisis (i.e., the killing of George Floyd).
During an interview for an upcoming feature in Life Science Leader, Sanjeev Redkar, Ph.D., cofounder and president of Apollomics (a biopharmaceutical company discovering and developing oncology treatments), discussed the topic of an exit strategy.
While working at his first job at Human Genome Sciences in 1995, Guo-Liang Yu, Ph.D., decided to create The Chinese Biopharmaceutical Association (CBA), one of the largest Chinese American professional associations in the U.S.
While we touch on remote work in Life Science Leader’s annual outlook issue, the responses in this article from four biopharmaceutical CFOs to questions on the subject shed additional light on the challenge that lies ahead for employers.
Two metropolitan areas tend to dominate the discussion when it comes to key biopharmaceutical industry hubs within the United States — Boston and San Francisco. And while these two cities have certainly earned their biopharma bragging rights over the years, one has to wonder how long that will continue. Afterall, just a few years ago biopharmaceutical executives noted it becoming increasingly difficult to attract top talent, as candidates cited “too crowded,” “too expensive,” and a host of other reasons behind their unwillingness to move to places like Boston and San Francisco. But does location (for many roles) even still apply?